[Jackie07]

Below is an abstract of a meta-analysis about tumor markers:

Clin Nucl Med. 2012 May;37(5):467-74.
Tumor Marker-Guided PET in Breast Cancer Patients-A Recipe for a Perfect Wedding: A Systematic Literature Review and Meta-Analysis.

Evangelista L, Cervino AR, Ghiotto C, Al-Nahhas A, Rubello D, Muzzio PC.
Source

From the *Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto (IOV-IRCCS), Padova, Italy; â€*Second Medical Oncology Unit, Istituto Oncologico Veneto (IOV-IRCCS), Padova, Italy; ‡Department of Nuclear Medicine, Hammersmith Hospital, London, United Kingdom; §Department of Nuclear Medicine, Radiology, Medical Physics, Santa Maria della Misericordia Hospital, Rovigo, Italy; and ¶Department of Radiology Oncology, Istituto Oncologico Veneto (IOV-IRCCS), Padova, Italy.

Abstract

INTRODUCTION:

: Early detection of breast cancer (BC) recurrence is a fundamental issue during follow-up. Although the utilization of new therapeutic protocols aimed at reducing the recurrence risk is defined, the diagnostic approach for early detection remains to be clarified. We aim to provide a critical overview of recently published reports and perform a meta-analysis on the use of tumor markers in BC patients as a guide for fluorodeoxyglucose positron emission tomography (PET) imaging.
METHODS:

: Medline and Google Scholar were used for searching English and non-English articles that evaluate the role of PET in BC recurrence when an increase in tumor markers is found. All complete studies were reviewed; thus, quantitative and qualitative analyses were performed.
RESULTS:

: From 2001 to May 2011, we found 19 complete articles that critically evaluated the role of PET in BC recurrence detection in the presence of elevated tumor markers. The meta-analysis of the 13 studies provided the following results: pooled sensitivity 0.878 (95% CI: 0.838-0.909), pooled specificity 0.693 (95% CI: 0.553-0.805), and pooled accuracy 0.828 (95% CI: 0.762-0.878).
CONCLUSIONS:

: The current experience confirms the potential of fluorodeoxyglucose PET, and in particular of PET/CT, in detecting occult soft tissue and bone metastases in the presence of a progressive increase of serum tumor markers in BC patients, but this should be better defined in the current practical recommendations.